Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Sep 19;20(1):9–18. doi: 10.1016/j.cgh.2020.09.036

Table 2.

Translational Liver Cancer Consortium Research Agenda

Screening Process Step Project
Risk stratification

  1. Identification of clinical and genetic risk factors for HCC in patients with NASH

  2. Derivation and validation of blood-based risk stratification biomarkers in patients with cirrhosis

  3. Identification of morphomic signatures from CT scans associated with HCC in patients with cirrhosis
Screening utilization

  1. Characterization of screening process failures and patient barriers contributing to screening underuse

  2. Evaluation of electronic medical record prompts to increase HCC screening use
Screening test effectiveness

  1. Validation of novel biomarker test performance in large cohorts, including methylated DNA markers and serum protein biomarkers

  2. Evaluation of novel imaging screening strategies such as abbreviated MRI

  3. Establish large cohorts of patients for biomarker and imaging validation

  4. Cost-effectiveness of screening strategies in patients with cirrhosis
Follow-up

  1. Characterization of screening-related harms in patients with cirrhosis

  2. Frequency and natural history of indeterminate nodules in patients with cirrhosis

CT, computed tomography; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; NASH, nonalcoholic steatohepatitis.